Dehydroandrographolide succinate

CAT: 0804-HY-N0677-01Size: 25 mgDry Ice: NoHazardous: No
CAT#:0804-HY-N0677-01Size:25 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED50 = 386.9 mg/kg) by decreasing TXB2 levels. Dehydroandrographolide succinate mitigates muscle astrophy via the Akt/GSK3β and MuRF-1 pathways[1][2][3].
CAS Number
[786593-06-4]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Akt; GSK-3; Influenza Virus; Prostaglandin Receptor
Type
Natural Products
Related Pathways
Anti-infection; GPCR/G Protein; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Neuroscience-Neuromodulation
Field of Research
Infection; Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/dehydroandrographolide-succinate.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(OC[C@]1(C)[C@H](OC(CCC(O)=O)=O)CC[C@@]2(C)[C@H](/C=C/C3=CCOC3=O)C(CC[C@]12[H])=C)CCC(O)=O
Molecular Formula
C28H36O10
Molecular Weight
532.58
Precautions
H302, H315, H319, H335
References & Citations
[1]Chen Q, et al. Pharmacokinetics and tolerance of dehydroandrographolide succinate injection after intravenousadministration in healthy Chinese volunteers. Acta Pharmacol Sin. 2012 Oct;33 (10) :1332-6.|[2]Bowen Yin, et al., The antithrombosis effect of dehydroandrographolide succinate: in vitro and in vivo studies. (2022) . The antithrombosis effect of dehydroandrographolide succinate: in vitro and in vivo studies. Pharmaceutical Biology, 60 (1), 175–184.|[3]Jin, H., et al., (2025) . Dehydroandrographolide succinate attenuates dexamethasone-induced skeletal muscle atrophy by regulating Akt/GSK3β and MuRF-1 pathways. European journal of pharmacology, 990, 177265.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Natural Products
Clinical Information
Launched

Related Products

CatalogName
HY-N0676Dehydroandrographolide
HY-N0676RDehydroandrographolide (Standard)
HY-150205-01Succinate/succinate receptor antagonist 1
HY-16170Desvenlafaxine (succinate)
HY-B0121-01Sumatriptan succinate
HY-109091B-01Lanraplenib (succinate)
HY-A0069-01Doxylamine (succinate)
HY-Y0836-01Diethyl succinate
HY-115014Cibenzoline (succinate)
HY-114458-01Monooctyl succinate

Alternative Products

CatalogName
M19106-01Dehydroandrographolide succinate
M39690-01Potassium sodium Dehydroandrographolide Succinate
MBS578533Dehydroandrographolide Succinate Potasium Salt
MBS5801122Dehydroandrographolide succinate potassium sodium salt
AB0276Dehydroandrographolide

Popular Products